Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett’s esophagus: a systematic review and meta-analysis

References

• Chang JT, Katzka DA. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med. 2004;164(14):1482–1488.
   Google Scholar
• Schlottmann F, Molena D, Patti MG. Gastroesophageal reflux and Barrett’s esophagus: a pathway to esophageal adenocarcinoma. Updates Surg. 2018;70(3):339–342.
   Google Scholar
• Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61(7):970–976.
   Google Scholar
• Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett’s oesophagus. Lancet. 2002;360(9345):1587–1589.
   Google Scholar
• Holmberg D, Ness-Jensen E, Mattsson F, et al. Clinical prediction model for tumor progression in Barrett’s esophagus. Surg Endosc. 2019;33(9):2901–2908.
   Google Scholar
• Kambhampati S, Tieu AH, Luber B, et al. Risk factors for progression of Barrett’s esophagus to high grade dysplasia and esophageal adenocarcinoma. Sci Rep. 2020;10(1):4899.
   Google Scholar
• Coleman HG, Xie SH, Lagergren J. The epidemiology of esophageal adenocarcinoma. Gastroenterology. 2018;154(2):390–405.
   Google Scholar
• Thrift AP. The epidemic of oesophageal carcinoma: where are we now? Cancer Epidemiol. 2016;41:88–95.
   Google Scholar
• Baruah A, Buttar NS. Chemoprevention in Barrett’s oesophagus. Best Pract Res Clin Gastroenterol. 2015;29(1):151–165.
   Google Scholar
• Elias PS, Castell DO. The role of acid suppression in Barrett’s esophagus. Am J Med. 2017;130(5):525–529.
   Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867.
   Google Scholar
• Peters Y, Al-Kaabi A, Shaheen NJ, et al. Barrett oesophagus. Nat Rev Dis Primers. 2019;5(1):35.
   Google Scholar
• Lee Y, Urbanska AM, Hayakawa Y, et al. Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett’s-like esophagus. Oncotarget. 2017;8(1):203–214.
   Google Scholar
• Pregun I, Herszényi L, Juhász M, et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion. 2011;84(1):22–28.
   Google Scholar
• Lanas A. Potent gastric acid inhibition in the management of Barrett’s oesophagus. Drugs. 2005;65(Suppl 1):75–82.
   Google Scholar
• Lowe D, Kudaravalli P, Hsu R. Barrett metaplasia. In: StatPearls. Treasure Island (FL): StatPearls PublishingCopyright © 2021, StatPearls Publishing LLC; 2021.
   Google Scholar
• Hu Q, Sun TT, Hong J, et al. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a systematic review and meta-analysis. PLoS One. 2017;12(1):e0169691.
   Google Scholar
• Singh S, Garg SK, and Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63(8):1229–1237.
   Google Scholar
• Chen Y, Sun C, and Wu Y, et al. Do proton pump inhibitors prevent Barrett’s esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis. J Cancer Res Clin Oncol. 2021;147(9): 2681–2691 .
   Google Scholar
• Shaheen NJ, Falk GW, and Iyer PG, et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50. quiz 51
   Google Scholar
• Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study. Am J Gastroenterol. 2011;106(8):1447–1455. quiz 1456
   Google Scholar
• Altawil J, Irwin B, Jinjuvadia R, et al. Can progression to dysplasia in Barrett’s esophagus be prevented by proton pump inhibitors? Am J Gastroenterol. 2011;106:S31.
   Google Scholar
• Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med J Aust. 2004;180(8):387–391.
   Google Scholar
• Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013;11(4):382–388.
   Google Scholar
• Nguyen DM, El-Serag HB, Henderson L, et al. Medication usage and the risk of neoplasia in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2009;7(12):1299–1304.
   Google Scholar
• Thota PN, Hajifathalian K, Benjamin T, et al. Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett’s esophagus: a cohort study. J Dig Dis. 2017;18(3):143–150.
   Google Scholar
• Gaddam S, Thota PN, Vennalaganti P, et al. Proton pump inhibitor use but not statin use is associated with decreased risk for high-grade dysplasia and esophageal adenocarcinoma in patients with barrett’s esophagus: results from a large, multicenter cohort study. Gastroenterology. 2014;146(5):S–123.
   Google Scholar
• Krishnamoorthi R, Borah B, Heien H, et al. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett’s esophagus cohort. Gastrointest Endosc. 2016;84(1):40–46.e47.
   Google Scholar
• De Jonge PJF, Steyerberg EW, Kuipers EJ, et al. Risk factors for the development of esophageal adenocarcinoma in Barrett’s Esophagus. Am J Gastroenterol. 2006;101(7):1421–1429.
   Google Scholar
• Hvid-Jensen F, Pedersen L, Funch-Jensen P, et al. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther. 2014;39(9):984–991.
   Google Scholar
• Masclee GMC, Coloma PM, Spaander MCW, et al. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett’s oesophagus: a populationbased case-control study. BMJ Open. 2015;5:1.
   Google Scholar
• Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, Statins, Proton Pump Inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology. 2010;138(7):2260–2266.
   Google Scholar
• Tan MC, El-Serag HB, Yu X, et al. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett’s oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018;48(4):469–477.
   Google Scholar
• Loomans-Kropp HA, Chaloux M, Richmond E, et al. 461 PROTON PUMP INHIBITOR AND STATIN USE DECREASE RISK OF ESOPHAGEAL ADENOCARCINOMA AMONG INDIVIDUALS WITH BARRETT’S ESOPHAGUS: a SEER-MEDICARE ANALYSIS. Gastroenterology. 2020;158(6):S-87-S-88.
   Google Scholar
• Jankowski JAZ, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392(10145):400–408.
   Google Scholar
• Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology. 1999;117(2):327–335.
   Google Scholar
• Peters FT, Ganesh S, Kuipers EJ, et al. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Scand J Gastroenterol. 2000;35(12):1238–1244.
   Google Scholar
• Fitzgerald RC, Lascar R, Triadafilopoulos G. Review article: barrett’s oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther. 2001;15(3):269–276.
   Google Scholar
• Zhang HY, Hormi-Carver K, Zhang X, et al. In benign Barrett’s epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks. Cancer Res. 2009;69(23):9083–9089.
   Google Scholar
• Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000;118(3):487–496.
   Google Scholar
• Souza RF, Huo X, Mittal V, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009;137(5):1776–1784.
   Google Scholar
• Souza RF. Reflux esophagitis and its role in the pathogenesis of Barrett’s metaplasia. J Gastroenterol. 2017;52(7):767–776.
   Google Scholar
• Dunbar KB, Souza RF, Spechler SJ. The effect of proton pump inhibitors on Barrett’s esophagus. Gastroenterol Clin North Am. 2015;44(2):415–424.
   Google Scholar
• Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54(11):2312–2317.
   Google Scholar
• Whitton B, Okamoto H, Packham G, et al. Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer. Cancer Med. 2018;7(8):3800–3811.
   Google Scholar
• Chueca E, Apostolova N, Esplugues JV, et al. Proton pump inhibitors display antitumor effects in barrett’s adenocarcinoma cells. Front Pharmacol. 2016;7:452.
   Google Scholar
• Yeh RW, Gerson LB, Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett’s esophagus. Dis Esophagus. 2003;16(3):193–198.
   Google Scholar
• Snider EJ, Kaz AM, Inadomi JM, et al. Chemoprevention of esophageal adenocarcinoma. Gastroenterol Rep (Oxf). 2020;8(4):253–260.
   Google Scholar
• Haigh CR, Attwood SE, Thompson DG, et al. Gastrin induces proliferation in Barrett’s metaplasia through activation of the CCK2 receptor. Gastroenterology. 2003;124(3):615–625.
   Google Scholar
• Abrams JA, Del Portillo A, Hills C, et al. Randomized controlled trial of the Gastrin/CCK(2) receptor antagonist netazepide in patients with Barrett’s esophagus. Cancer Prev Res (Phila). 2021;14(6):675–682.
   Google Scholar
• Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48.
   Google Scholar
• Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12(12):1063–1073.
   Google Scholar
• Souza RF, Shewmake K, Beer DG, et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000;60(20):5767–5772.
   Google Scholar
• Zhang S, Zhang XQ, Ding XW, et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a meta-analysis. Br J Cancer. 2014;110(9):2378–2388.
   Google Scholar
• Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett’s esophageal adenocarcinoma cells. Am J Gastroenterol. 2008;103(4):825–837.
   Google Scholar
• Thomas T, Loke Y, Beales ILP. Systematic review and meta-analysis: use of statins is associated with a reduced incidence of oesophageal adenocarcinoma. J Gastrointest Cancer. 2018;49(4):442–454.
   Google Scholar